Chondrocytes regulate cartilage homeostasis by balancing the synthesis of matrix molecules (Col-II, proteoglycans, aggrecan, etc.) and degrading enzymes (MMPs, ADAMTs, etc.) (Goldring and Marcu, 2009). Physiological loading helps to maintain the integrity of cartilage by decreasing activities of MMPs and suppressing pro-inflammatory factors, but promoting the secretion of more ECM (Wong et al., 1999; Bonassar et al., 2001; Mauck et al., 2003; Goldring and Marcu, 2009; Ng et al., 2009; Leong et al., 2011; Torzilli et al., 2011). Dynamic loading also facilitates transport of molecules throughout the cartilage using convection, which is faster compared to diffusion (Mow et al., 1994; Grodzinsky et al., 2000; Quinn et al., 2001; Evans and Quinn, 2006a; Evans and Quinn, 2006b; Chahine et al., 2009). The transition from healthy to diseased cartilage occurs through an imbalance in the metabolism (catabolic and anabolic reactions) of ECM. Under injurious loading, inflammation promotes enzymatic degradation of ECM proteins through increased MMP activity, resulting in the loss of proteoglycan and other structural matrix components (Sanchez-Adams et al., 2014; Fukui et al., 2015). This matrix degradation alters compressive stiffness and shear resistance of cartilage (Boschetti and Peretti, 2008; Wong et al., 2008; Maier et al., 2019; Mieloch et al., 2019).

In the early phase of OA, these changes are pronounced in the PCM, the extracellular environment immediately surrounding the chondrocyte (Wilusz et al., 2014). In particular, chondrons (chondrocytes and their surrounding PCM) from human OA cartilage experience about 40% reduction in Young’s elastic moduli and 66% more compressive strains than their healthy counterparts (Alexopoulos et al., 2003; Alexopoulos et al., 2005). Aggrecan is synthesized primarily in the PCM and turns over at a faster rate in the PCM than in the surrounding territorial domain ECM (Quinn et al., 1999). During OA related degradation, aggrecan is the first component of the matrix to be degraded (Lark et al., 1995; Han et al., 2011; Chery et al., 2020). Chery et al. performed destabilization of the medial meniscus (DMM) surgery on mouse knees, an injury model of OA progression, and showed that decrease in the PCM compressive modulus occurs about 3-days post-injury, which correlated with a reduction in aggrecan staining seen in the PCM. This decrease in modulus was lower in the PCM than surrounding ECM, suggesting that changes related to OA first occur in the PCM (Guilak et al., 2018; Chery et al., 2020). Compressive modulus in the PCM was further decreased as OA progressed. Blocking of PCM degradation with GM6001, an MMP and aggrecanase inhibitor, lead to an increase in PCM modulus after injury, suggesting PCM integrity at early stages of OA is important to maintaining joint health (Chery et al., 2020). Yet, several experimental therapies targeting MMPs have not been successful in preventing cartilage degradation (Krzeski et al., 2007; Grässel and Muschter, 2020). On the other hand, TRPV4, Piezo1, and Piezo2 channels play a role in Ca²⁺ signaling dependent on substrate stiffness. Specifically, TRPV4 responds to stiffer substrates, while Piezo1/2 to less stiff substrates, making these ion channels potential targets for OA treatment (Du et al., 2021).

Transient Receptor Potential Vanilloid 4 (TRPV4) is a cation channel that allows influx of Ca²⁺, mediating anabolic responses of chondrocytes triggered by physiological loading (Figure 1A) (Nilius et al., 2003; Hattori et al., 2021); thus, TRPV4 is a potential therapeutic target for OA treatment. TRPV4 is more sensitive to osmotic pressure as a result of increasing charge density by cartilage compression, suggesting that TRPV4 activation is stimulated by osmotic stress transduced from mechanical loading (Sánchez et al., 2014; Lv et al., 2018; Nims et al., 2021). In addition, TRPV4 has been shown to have a delay in Ca²⁺ response after osmotic stimulation (Lv et al., 2018). In vitro experiments involving the use of TRPV4 agonist (GSK101) and antagonist (GSK205) found that TRPV4-mediated Ca²⁺ signaling plays an essential role in the transduction of mechanical stimuli to reinforce and maintain the cartilage matrix and joint health. Physiological loading in this case was defined as 10% strain. TRPV4 activation resulted in an increase in Col-II and sulfated glycosaminoglycans (GAGs) in cartilage. However, chondrocytes with GSK205 in the presence of a mechanical load expressed significantly lower levels of Col-II and higher levels of MMPs (O'Conor et al., 2014; Trompeter et al., 2021a; Savadipour et al., 2022). The effect of TRPV4 activation using GSK101 has been observed to be analogous to that of a mechanical load; chondrocytes treated with GSK101 decrease the synthesis of pro-inflammatory molecules and degradative enzymes (Fu et al., 2021).

TRPV4 has been noted as a possible sensor for excessive stress, resulting in chondrocyte apoptosis (Xu et al., 2019). However, the loading procedure performed in this study was direct stimulation (20% stretch) to the chondrocytes. As TRPV4 channels are usually activated by osmotic stresses, the difference in stimulation mode as well as the hyper-physiological strain on the chondrocytes may have caused cell death, a different effect than the usual anabolic pathway that TRPV4 mediates under physiologic loads.

In vivo experiments have also highlighted the essential role of TRPV4 channels for cartilage health and disease. Mice with cartilage-specific TRPV4-deletion in adulthood exhibit reduced severity of aging-associated OA compared to control mice; however, analysis following DMM injury show similar levels of cartilage degradation and OA severity between control and TRPV4-deficient mice (O'Conor et al., 2016). This suggests that age-related and post-traumatic osteoarthritis (PT-OA) are mediated through distinct pathways. As TRPV4 inhibition did not prevent the progression of OA after injury, it is not a suggested therapeutic strategy for PT-OA treatment (O'Conor et al., 2016). The reduced aging-OA phenotype in cartilage of TRPV4-deleted mice may be due to imbalanced matrix metabolism, or redundancy in the mechanotransduction pathways that may compensate for TRPV4-deletion (Servin-Vences et al., 2017). In short, these collective data demonstrate the essential roles of TRPV4 in cartilage maintenance and anabolism (O'Conor et al., 2014).

Piezo1 and Piezo2 channels are mammalian-expressing mechanosensitive cation channels discovered in 2010 that allow passage of Ca²⁺ into chondrocytes (Coste et al., 2010; Coste et al., 2012). Both Piezo1 and 2 channels are directly and rapidly activated by mechanical cues (τ_{ac_Piezo1} < 5 msec) with rapid subsequent inactivation time (τ_{inac_Piezo1}∼ 16 msec, τ_{inac_Piezo2} ∼ 7 msec) (Coste et al., 2010). Yet, these channels have distinct gene expression patterns and are associated with different types of human diseases. Piezo1 is robustly expressed in mechanically stimulated tissues, including lung, colon, bladder, kidney, blood vessels, and in cells, including red blood cells, cardiac fibroblasts, and smooth muscle cells (Xu et al., 2020). Activated by mechanical forces at the cell membrane, Piezo1 channels mediate responses in the cell, such as adjusting cell volume or remodeling host tissue, through activation of intracellular signaling pathways. Mutations in the Piezo1 channel are associated with lymphatic dysplasia and hemolytic anemia (Syeda et al., 2015; Xu et al., 2020). In contrast, Piezo2 channels are highly expressed in sensory systems, including proprioceptive mechanosensors and Merkel cells, controlling limb movement and touch sensation (Xu et al., 2020; Fang et al., 2021). Mutations in Piezo2 lead to muscular atrophy, distal arthrogryposis, and scoliosis arthrogryposis (Anderson et al., 2017; Assaraf et al., 2020).

Articular chondrocytes express both Piezo1 and Piezo2 channels (Piezo1/2) robustly, and both channels are key mechanotransducers sensing injurious level (high-strain) mechanical loads (Lee et al., 2014; Du et al., 2020). Compression with a strain of ∼50% by atomic force microscopy (AFM) probes on isolated chondrocytes leads to a significant and prolonged intracellular Ca²⁺ influx with τ_{inac_chondrocyte} ∼ 16 s (not msec). These robust Ca²⁺ transients were diminished in chondrocytes with either Piezo1-knockdown or Piezo2-knockdown, as well as with GsMTx4 (an inhibitor of both Piezo1 and Piezo2) or verapamil [an inhibitor of L-type voltage-gated Ca²⁺ channels (VGCC)] treatment. These data suggest the synergistic action of Piezo1 and Piezo2 in transducing mechanical signals, and the role of VGCC in amplifying intracellular Ca²⁺ after Piezo1/2 activation (Figure 1B). The synergistic activation of Piezo1 and Piezo2 channels were further seen in heterologous cells with co-transfection of Piezo1 and Piezo2 under AFM-based compression or electrophysiology-based membrane stretch, but not in model cells with only-Piezo1 or only-Piezo2 transfections (Lee et al., 2014). The chondroprotective effect of Piezo1/2 inhibition using GsMTx4 was shown in a cartilage explant injury model, where porcine osteochondral explants were injured with a biopsy punch, resulting in chondrocyte damage at the area of injury. GsMTx4 pre-incubation of the explants was shown to decrease the “zone of death,” or damaged area, demonstrating GsMTx4’s effect of protecting chondrocytes from mechanical trauma via Piezo1/2 inhibition (Lee et al., 2014; Lawrence et al., 2017). GsMTx4 will be explored further as a potential therapeutic in a later section.

Osteoarthritic joints and acutely injured joints exhibit significantly increased levels of interleukin-1 (IL-1) cytokines with enhanced inflammatory signaling in chondrocytes. Chondrocytes express functional IL-1 receptor (IL1R) and respond to both isoforms of IL-1α and IL-1β (Martel-Pelletier et al., 1992; McNulty et al., 2013). IL-1α-treatment increases Piezo1 preferentially, but not Piezo2 or TRPV4 channels, in primary articular chondrocytes. Chondrocytes in porcine and human OA cartilage also express 2-fold Piezo1 channels compared to healthy cartilage (Lee et al., 2021). Piezo1 augmentation further increases hyper-mechanosensitivity of chondrocytes in vitro (Figure 1B). AFM-based assay data reveal the increased Ca²⁺ influx from cyclic physiologic loading in IL-1α-treated or Yoda1 (a Piezo1-specific agonist) chondrocytes compared to controls, which in turn was diminished by co-treatment with Piezo1-siRNA or GsMTx4. These data suggest Piezo1’s role in the inflammatory response, disrupting Ca²⁺ homeostasis and increasing mechano-sensitivity of chondrocytes to mechanical loads.

Inflammation also affects the cytoskeleton, particularly filamentous actin (F-actin), as force transduction through F-actin is important in chondrocyte mechanotransduction (Wang et al., 1993; Haudenschild et al., 2008; Trompeter et al., 2021b; Dieterle et al., 2021). With exposure to IL-1α, F-actin of primary chondrocytes was reduced—an effect that was also seen in human OA cartilage samples. However, F-actin was restored with Piezo1 inhibition via GsMTx4 or Piezo1-targeting siRNA. Exposure to IL-1α also resulted in a decrease in cellular Young’s modulus, leading to increased cellular deformation with the same magnitude of mechanical loading compared to control samples. Inhibition of Piezo1 returned the cellular modulus and cell deformation to control levels. This shows that influx of Ca²⁺ through Piezo1 can affect cytoskeletal components including F-actin, resulting in a decrease in mechanical stiffness of the chondrocyte, increasing the likelihood of tissue degeneration. IL-1α-treatment also augmented Piezo1 via p38-MAPK signaling pathways and ATF2/CREBP1/HNF4 transcription factors (TFs). Testing of MAP-kinases downstream of IL1R showed that inhibition of p38-MAP kinase led to a decrease in Piezo1 mRNA expression with IL-1α exposure. Screening for TFs showed that inhibition of ATF2/CREBP1 and HNF4 attenuated Piezo1 mRNA expression in response to IL-1α.

Altogether, inflammatory cytokine IL-1α activates IL1R, where the signal is transduced by p38-MAPK, resulting in the activation of Piezo1 expression through TFs, ATF2/CREBP1 and HNF4. The increased expression of Piezo1 can result in increased Ca²⁺ influx, resulting in the loosening of the F-actin network (Lee et al., 2021). This can decrease cellular stiffness, and in turn decrease tissue stiffness, increasing the chance of developing an OA phenotype.

Piezo2 channels expressed in intra-articular sensory neurons have been studied in the context of nociception, mediating inflammation and nerve injury-induced sensitized mechanical pain or mechanical allodynia. Piezo2 expression is high in low threshold mechanoreceptors, likely contributing to their sensitivity to mechanically activated pain. Knockout of Piezo2 in mice impaired nociceptor firing, resulting in disrupted responses to noxious mechanical stimuli (Murthy et al., 2018). In a study by Szczot et al., Piezo2 mediated inflammation-induced pain in tactile allodynia. With Piezo2 knockout, mice failed to develop sensitization and pain in response to touch after skin inflammation, suggesting a possible role of Piezo2 in mediating pain sensation under inflammation (Szczot et al., 2018).

There has been ongoing investigation of the role of Piezo2 in OA mediated pain, however, the mechanism of this pain transduction pathway is not yet completely understood. Miller et al. studied pain reactions in mice with homozygous or heterozygous Piezo2 deletion in a DMM surgery-induced mouse OA model. In wild-type mice with intact Piezo2, knee hyperalgesia and mechanical allodynia of the ipsilateral hind paw developed 4-weeks post-surgery. Less mechanical allodynia was seen with heterozygous deletion of Piezo2 4-weeks after DMM, however, knee hyperalgesia did not change compared to the mice with intact Piezo2. In mice with Piezo2 homozygous deletion, less knee hyperalgesia and mechanical allodynia was seen in the hind paw at 4-weeks post-DMM surgery (Miller et al., 2019). In further study, it was shown that conditional knockout of Piezo2 in mice lead to attenuated nerve growth factor (NGF)-mediated knee swelling and mechanical pain (Obeidat et al., 2022). These data suggest an essential role of Piezo2 in mediating OA-associated joint nociceptor sensitization.

The goal of OA therapeutics is to prevent progressive cartilage degeneration and joint dysfunction. OA therapeutics are urgently needed especially for younger patients who have a high risk for PT-OA a decade after joint injury (Anderson et al., 2011; Schenker et al., 2014; Krishnan and Grodzinsky, 2018; Eskelinen et al., 2020). Exercise and physical therapies are currently suggested after surgery to promote anabolism, presumably by targeting the TRPV4 ion channels. In addition to exercise, patients may receive intra-articular injections of hyaluronic acid (HA) or corticosteroids, to increase cartilage lubrication or decrease local inflammation, respectively. HA is a GAGs found in the cartilage and synovial fluid, which provides the joint with lubrication and shock absorbance (Fusco et al., 2021). With OA progression, HA in the synovial fluid usually depolymerizes from high to low molecular weight, resulting in a decline in mechanical and viscoelastic properties of the joint. Exogenous injection of HA can promote synthesis of extracellular matrix proteins, proteoglycans, and/or GAGs, and have anti-inflammatory effects (Bowman et al., 2018). Usually used for short-term pain-relieving treatment, HA injection has shown to provide some pain relief, however, injections are expensive (Trigkilidas and Anand, 2013; Liu et al., 2018). Some patients also receive intra-articular injections of corticosteroids, which have immunosuppressive and anti-inflammatory effects on the joint, blocking synthesis of pro-inflammatory molecules (IL-1) and catabolic proteins (MMPs). Patients with joint inflammation caused by OA benefit more with corticosteroid injection, compared with HA. However, corticosteroid treatment provides only temporary, short term pain relief (Ayhan et al., 2014; Fusco et al., 2021; Primorac et al., 2021).

The above therapies are limited in that they only control the symptoms of OA after disease onset and progression, and they are used as conservative therapies before the need for surgical intervention. Disease-modifying OA drugs (DMOAD) are currently being investigated with the goal to halt cartilage degradation, promote matrix regeneration, and reduce OA-mediated pain. This includes therapies aiming to inhibit MMPs, like MMP-13 and aggrecanases, to prevent the degradation of cartilage matrix that occurs in OA (Kurz et al., 2005; Chubinskaya et al., 2015). A clinical trial was conducted for MMP inhibitor PG-116800 to test its ability to delay cartilage destruction. PG-116800 has high affinity for MMP-2, -3, -8, -9, -13, and -14, and low affinity for MMP-1 and MMP-7. The trial was terminated due to a musculoskeletal toxicity side effect. There was also no significant difference in radiographic knee joint space between treatment and placebo groups, suggesting the therapy was ineffective in preventing degradation of cartilage. The major adverse effect seen was arthralgia. The investigators hypothesized that the musculoskeletal symptoms may have been due to MMP inhibitors ability to inhibit sheddase activity, which normally converts cytokines into inactive forms (Krzeski et al., 2007). Inhibition of this activity would then result in paradoxical inflammation. Another hypothesis made was that the toxicity was due to MMP-1 inhibition. Efforts to develop a selective compound to target inactivation of only MMP-13 are in progress, but results are forthcoming (Baragi et al., 2009; Vandenbroucke and Libert, 2014; Li et al., 2017).

Other therapies targeting inflammatory cytokines active in OA, like IL-1, IL-6, and TNF-α, have been studied as well (Jacques et al., 2006; Chubinskaya et al., 2015). Most of these therapeutics were originally developed for treatment of rheumatoid arthritis (RA) and adapted to treat OA. However, these treatments were ultimately ineffective in preventing pain or cartilage degradation. An example is anakinra, an IL-1 receptor antagonist. Investigators attributed this lack of effectiveness due to the mode of treatment administration, a single intra-articular injection to the knee (Chevalier et al., 2009). Further studies are anticipated to investigate more long-lasting, potent IL-1 receptor antagonists (Jotanovic et al., 2012).

Senescent cells have also been targeted since these cells are accumulated in areas of cartilage degeneration in OA. Senescence has been shown to promote oxidative stress and inflammation in diseased cartilage (Vinatier et al., 2018). A senolytic molecule, UBX0101, was developed to remove these cells by inhibiting MDM2/p53 interactions, reducing the release of inflammatory factors and associated pain (Loeser, 2011; Collins et al., 2018; Hsu et al., 2019; Coryell et al., 2021). However, this trial of UBX0101 intra-articular injection was discontinued as it failed to meet week-12 primary endpoints, with no significant difference between treatment and placebo groups (Hsu et al., 2019; Grässel and Muschter, 2020).

GsMTx4, a 34 amino acid peptide derived from tarantula venom, inhibits Piezo1 and Piezo2 channels (Bowman et al., 2007; Gottlieb et al., 2007; Copp et al., 2016; Alcaino et al., 2017). GsMTx4 anchors to the outer membrane surface by lysine residue at low tension. When the membrane is under tension, GsMTx4 is able to physically sink deeper into the membrane, leading to partial relaxation of the outer monolayer of the membrane. This disrupts the distribution of tension near mechanosensitive channels including Piezo1, causing a less efficient transfer of force from the bilayer to the channel without physical block of ion pore regions. The change in membrane tension creates a 30 mmHg rightward shift in the pressure-gating curve, making it harder for Piezo1 to open under mechanical stimulation (Bae et al., 2011; Gnanasambandam et al., 2017). GsMTx4 has been shown to be ineffective in inhibiting TRPV4 channels, demonstrated in juxtaglomerular cells, bladder urothelium, and endothelial cells (Seghers et al., 2016; Ihara et al., 2018; Swain and Liddle, 2021). In chondrocytes, GSK205 (a TRPV4 inhibitor) failed to inhibit Ca²⁺ influx under hyperphysiological loading, while GsMTx4 treatment did, further confirming GsMTx4’s ability to selectively inhibit Piezo channels. A possible mechanism as to why GsMTx4 is specific to Piezo may be due to the unique structure of these channels. Piezo channels have three curved, blade-like structures that widen from the base of the protein to the mechanosensing portion on the outer layer of the plasma membrane (Fang et al., 2021). This may allow GsMTx4 to embed closer to the Piezo channel and influence membrane tension more locally, effecting Piezo channel activation specifically.

The use of GsMTx4 has been studied in the treatment of Duchenne muscular dystrophy (DMD). DMD is caused by genetic mutation resulting in a loss of dystrophin, which is linked to increased permeability of the sarcolemma to extracellular Ca²⁺. This leads to a decline in muscle mass due to increased Ca²⁺-dependent proteolysis and necrosis of muscle fibers. GsMTx4-D, an enantiomer of GsMTx4, was shown to decrease loss in muscle mass and improve the muscle’s functional capacity due to inhibiting mechanically stimulated channels like Piezo1 (Suchyna, 2017). Ward et al. studied the pharmacokinetics of GsMTx4 in mice. Through 50 mg/kg dose subcutaneous injection, GsMTx4 accumulation of 0.1–5 μM in skeletal muscle and heart was achieved within 24 h, a range shown to effectively limit MA channel activity. GsMTx4 also demonstrated long half-life in tissues, but rapid depletion in the blood, suggesting higher affinity of GsMTx4 for tissues than serum proteins. D-amino acid peptides are less prone to enzymatic degradation, which may contribute to GsMTx4-D’s long half-life. No apparent adverse effects or signs of toxicity were shown during the 6-weeks study in mice, although further study of long-term effects, particularly on growth and development, would be needed (Ward et al., 2018).

A cardio-protective effect was also seen with use of GsMTx4 in the context of cardiac ischemic reperfusion injury, which is often associated with an elevation of Ca²⁺ influx. Wang et al. showed that mice with intravenous injection of GsMTx4-D during an ischemic event or with subcutaneous injection prior to ischemic challenge show reduced infarct size, less arrhythmic activity, and increased cardiac output post ischemia. GsMTx4 treatment also improved heart contraction by restoring normal Ca²⁺ release and blocked apoptotic signaling to improve cardiomyocyte survival. Slowing of cation influx through ion channels with GsMTx4 during ischemia and reperfusion prevented cell swelling that occurs with cation overload. GsMTx4 was mostly active at pathological conditions, as there was little effect of the treatment on normally functioning controls (Wang et al., 2016).

In the context of OA, GsMTx4-treated cartilage demonstrates a chondroprotective effect in hyper-physiological loading by inhibiting Piezo1 and Piezo2 channels. Osteochondral cartilage explants with pre-incubation of GsMTx4 showed significantly decreased chondrocyte damage and death after biopsy punch injury (Lee et al., 2014). GsMTx4 was also shown to prevent inflammation-induced rarefication or loosening of F-actin, an important cytoskeleton component in chondrocyte mechanotransduction. Inhibition of the Piezo1 channel via GsMTx4 preserved the cellular modulus in the presence of IL-1α as well (Lee et al., 2021). To date, the effect of GsMTx4 in the context of articular cartilage injury has been studied in in vitro and ex vivo models. Moving forward, further study would be needed to see whether the chondroprotective effect translates to in vivo animal models and potential clinical use. Along with this, appropriate dosing for intra-articular injection of GsMTx4 would need to be determined, as well as any potential toxicities related to long term use of GsMTx4. Based on its application to treatment of other disease, GsMTx4 seems to be nontoxic and effective in treating pathologies related to Piezo1 channel dysfunction.

As an FDA-approved drug, verapamil has been used in the treatment of various cardiac conditions including angina, arrhythmias, and hypertension, with no major adverse effects observed (Brogden and Benfield, 1996; De Simone et al., 2003). A commonly prescribed L-type voltage-gated calcium channel (VGCC) blocker, verapamil has also been studied as a therapeutic to attenuate Wnt/β-catenin signaling in OA (Matta et al., 2015; Vaiciuleviciute et al., 2021). The activation of β-catenin can induce hypertrophic differentiation of chondrocytes and upregulate ECM catabolic enzymes, leading to development of an OA-phenotype (De Santis et al., 2018; Wang et al., 2019; Lories and Monteagudo, 2020). Verapamil is able to suppress Wnt/β-catenin signaling by enhancing FRZB gene expression, an antagonist of Wnt signaling, which leads to suppressed ECM degradation (lower MMP activity), enhanced gene expression of aggrecan and Col-II, and decreased hypertrophic differentiation of chondrocytes (lower type X collagen expression). In a study by Takamatsu et al., 50 μM of verapamil was delivered to rats intra-articularly after DMM, preventing progression of OA without apparent adverse effects, although long term use in clinical practice needs further investigation (Takamatsu et al., 2014).

In their investigation of chondrocytes, Lee et al. suggest that Piezo1 activation may lead to activation of VGCCs, amplifying intracellular Ca²⁺ signaling in response to injurious loading. Verapamil was shown to decrease the Ca²⁺ transients in response to injurious compression, suggesting that VGCCs may be activated in addition to Piezo1 with hyper-physiological loading, as opposed to Ca²⁺ movement via TRPV4 in response to hypo-osmotic stress (Lee et al., 2014; Nims et al., 2021). This may indicate a correlation between Piezo1, VGCCs and Wnt signaling which are all activate during injurious loading. Further study is needed to confirm Piezo1’s direct effect on Wnt signaling in chondrocytes.

Targeting OA-associated chondrocyte mechanotransduction shows promise as future therapeutics for OA. Based on current knowledge, OA therapeutic strategies would be to promote TRPV4-mediated cartilage anabolism and to inhibit Piezo1-mediated chondrocyte death and inflammatory feed-forward responses. These strategies may be achieved by administrations of GSK101, GsMTx4, and verapamil (Figure 1C). Intra-articular injections are suggested to specifically target tissues in synovial OA joints, reducing systemic side effects to other organ systems, in addition to increasing the drug’s bioavailability. The use of mechanoresponsive biomaterials can further control the delivery of drugs (Geiger et al., 2018). For example, nanoparticles containing these drugs may release its contents into the joint space over time, generating a sustained release. Release of a drug can also be controlled based on compressive, tensile, or shear forces applied to a hydrogel containing the drug. Specifically, in this application, a hydrogel may be tuned to release GsMTx4 under hyper-physiological loads (ex. >300 nM compression), thus, releasing the drug only as needed. This technology may increase the longevity of a single treatment and reduce overall treatment costs over time (Hodgkinson et al., 2021).